Drug Profile
Research programme: metabolic disorders therapy - Boehringer/Evotec SE
Latest Information Update: 27 Sep 2019
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim; DeveloGen
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Obesity; Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in Germany
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in Germany
- 02 Sep 2010 DeveloGen has been acquired by Evotec AG